Floatz logo

Lidocaine

Head And Neck Cancer

Instituto Nacional de Cancer, BrazilSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

141 Active assets in the Head And Neck Cancer cohort.

Asset / SponsorPhaseRating
NEPENTHE
Instituto Nacional de Cancer, Brazil
Phase 4BB
Cis-Diamminedichloroplatinum Ii
ImmunityBio, Inc.
Phase 3BB
Carboplatin
Rapa Therapeutics LLC
Phase 3BB
Nivestim
University of Colorado, Denver
Phase 2BB
Cetuximab
Pfizer
Phase 3BB

View all 50 →

Same molecule, other indications

Lidocaine is also rated in:

peripheral neuropathyActive
BBB
Indicative · Phase 4
79 / 100
View asset →
postherpetic neuralgiaDormant
BBB
Indicative · Phase 4
78 / 100
View asset →
post-operative pain, non-human animalActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →